Faculty Profiles - MORISE Masahiro

Papers - MORISE Masahiro

Division display 41 - 60 of about 93 ／ All the affair displays >>

Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer A retrospective observational study Reviewed International journal

Oi, H; Matsuda, T; Kimura, T; Morise, M; Yamano, Y; Yokoyama, T; Kataoka, K; Kondoh, Y

MEDICINE Vol. 101 ( 6 ) page： e28863 2022.2

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations Reviewed International journal

Tanaka, I; Morise, M

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Vol. 23 ( 1 ) 2022.1

Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer Reviewed International journal

Matsuzawa Reiko, Morise Masahiro, Tanaka Ichidai, Hayai Shunsaku, Tamiya Yutaro, Koyama Junji, Hase Tetsunari, Wakahara Keiko, Kim Deoksu, Shimoyama Yoshie, Hashimoto Naozumi

Internal Medicine Vol. 61 ( 5 ) page： 703 - 708 2022

Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Internal Medicine

Amelanotic melanoma is a rare type of melanoma that shows little or no melanin pigmentation. When tumor lesions are not detected in cutaneous sites, the presence of melanin is the hallmark sign of malignant melanoma. We herein report a case of amelanotic melanoma with a BRAF V600E mutation mimicking primary lung cancer that was finally diagnosed on an autopsy. The current case suggests important caveats for the differential diagnosis of patients with BRAF V600E mutation-positive poorly differentiated lung tumors. In terms of the pathological diagnosis, routine immunohistochemical staining may be useful, especially in patients with a poorly differentiated lung tumor without TTF-1 expression.

DOI： 10.2169/internalmedicine.6657-20

Web of Science

PubMed

CiNii Research

Is area under the curve the best parameter for carboplatin induced emetic risk stratification? Reviewed International journal

Ozone, S; Ichikawa, K; Morise, M; Matsui, A; Kinoshita, F; Matsuzawa, R; Koyama, J; Tanaka, I; Hashimoto, N

NAGOYA JOURNAL OF MEDICAL SCIENCE Vol. 83 ( 4 ) page： 773 - 785 2021.11

Oxytocin receptor is a promising therapeutic target of malignant mesothelioma Reviewed International journal

Kodama, Y; Tanaka, I; Sato, T; Hori, K; Gen, S; Morise, M; Matsubara, D; Sato, M; Sekido, Y; Hashimoto, N

CANCER SCIENCE Vol. 112 ( 9 ) page： 3520 - 3532 2021.9

The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence Reviewed International journal

Tanaka, I; Furukawa, T; Morise, M

CANCER CELL INTERNATIONAL Vol. 21 ( 1 ) page： 454 2021.8

Tepotinib in patients with NSCLC harbouring METexon 14 skipping: Japanese subset analysis from the Phase II VISION study Reviewed International journal

Sakai, H; Morise, M; Kato, T; Matsumoto, S; Sakamoto, T; Kumagai, T; Tokito, T; Atagi, S; Kozuki, T; Tanaka, H; Chikamori, K; Shinagawa, N; Takeoka, H; Bruns, R; Straub, J; Schumacher, KM; Paik, PK

JAPANESE JOURNAL OF CLINICAL ONCOLOGY Vol. 51 ( 8 ) page： 1261 - 1268 2021.8

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study Reviewed International journal

Nakano, T; Kuribayashi, K; Kondo, M; Morise, M; Tada, Y; Hirano, K; Hayashi, M; Tanaka, M; Hirabayashi, M

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 ( 3 ) page： 264 - 272 2021.6

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma Reviewed International journal

Nakagawa, K; Kijima, T; Okada, M; Morise, M; Kato, M; Hirano, K; Fujimoto, N; Takenoyama, M; Yokouchi, H; Ohe, Y; Hida, T; Aoe, K; Kishimoto, T; Hirokawa, M; Matsuki, H; Kaneko, Y; Yamada, T; Morimoto, C; Takeda, M

JTO CLINICAL AND RESEARCH REPORTS Vol. 2 ( 6 ) page： 100178 2021.6

Evaluation of reactivity of HISCLTM SARS-CoV-2 antibody reagent Reviewed International journal

KIKUCHI Ryosuke, SUZUKI Atsuo, KIM Jeong Hui, WATARAI Rika, MORISE Masahiro, SAITO Shoji, YAGI Tetsuya, MATSUSHITA Tadashi

Japanese Journal of Medical Technology Vol. 70 ( 2 ) page： 220 - 227 2021.4

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Japanese Association of Medical Technologists

Antibody detection reagents for the novel coronavirus SARS-CoV-2 can be classified into two types: those that detect antibodies to the spike protein S1 domain (S) and/or the nucleocapsid protein (N) of SARS-CoV-2. In this study, we evaluated the reactivity of the HISCLTM SARS-CoV-2 antibody reagent in three cases of COVID-19. In case 1, IgM antibodies were detected when using the HISCLTM SARS-CoV-2 S-IgM reagent from the time of admission to the hospital (day X). In case 2, SARS-CoV-2 antibodies were detected when using the HISCL SARS-CoV-2 S-IgM, N-IgM, and N-IgG reagents from the X + 1st day, and IgG antibodies were detected from the X + 2nd day when using the HISCLTM SARS-CoV-2 S-IgG reagent . In case 3, positive results were obtained from X + 12th day for the HISCLTM SARS-CoV-2 S-IgM and S-IgG reagents. These results suggest that among the HISCLTM SARS-CoV-2 reagents, the S-targeting antibody reagent could detect SARS-CoV-2 antibodies earlier than the N-targeting antibody reagent.

DOI： 10.14932/jamt.20-131

CiNii Research

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations Reviewed International journal

Ninomiya, K; Teraoka, S; Zenke, Y; Kenmotsu, H; Nakamura, Y; Okuma, Y; Tamiya, A; Nosaki, K; Morise, M; Aokage, K; Oya, Y; Kozuki, T; Sakamoto, T; Tanaka, K; Tanaka, H; Tanizaki, J; Miura, S; Mizutani, H; Miyauchi, E; Yamaguchi, O; Ebi, N; Goto, Y; Sasaki, T; Daga, H; Morita, S; Yamanaka, T; Amano, S; Hasegawa, K; Imamura, CK; Suzuki, K; Nakajima, K; Nishimoto, H; Oizumi, S; Hida, T; Hotta, K; Takiguchi, Y

JTO CLINICAL AND RESEARCH REPORTS Vol. 2 ( 1 ) page： 100107 2021.1

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET) Reviewed International journal

Takeuchi, S; Yanagitani, N; Seto, T; Hattori, Y; Ohashi, K; Morise, M; Matsumoto, S; Yoh, K; Goto, K; Nishio, M; Takahara, S; Kawakami, T; Imai, Y; Yoshimura, K; Tanimoto, A; Nishiyama, A; Murayama, T; Yano, S

TRANSLATIONAL LUNG CANCER RESEARCH Vol. 10 ( 1 ) page： 314 - 325 2021.1

Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series International journal

Ishi Azusa, Tanaka Ichidai, Iwama Shintaro, Sakakibara Toshihiro, Mastui Toshinori, Kobayashi Tomoko, Hase Tetsunari, Morise Masahiro, Sato Mitsuo, Arima Hiroshi, Hashimoto Naozumi

Endocrine Journal Vol. 68 ( 5 ) page： 613 - 620 2021

Language：English Publishing type：Research paper (scientific journal) Publisher：The Japan Endocrine Society

The programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis is vital for immune resistance during tumor development, while PD-L1 inhibitors can also inhibit the PD-L1/B7-1 (CD80) interaction, indicating one of the molecular differences between PD-1 and PD-L1 inhibitors. However, the clinical benefits of PD-L1 inhibitors in patients previously treated with PD-1 inhibitors remain unknown. In this study, we retrospectively analyzed the clinical data of eight patients with non-small cell lung cancer who received the PD-L1 inhibitor atezolizumab and previously treated with the PD-1 inhibitor nivolumab. The median progression-free survival was 2.1 months (1.8–18.7 months), and 4 of 8 patients achieved at least stable disease. In two of these patients, atezolizumab treatment resulted in longer progression-free survival (PFS) compared with that of nivolumab. Conversely, one patient exhibited grade 4 diabetic ketoacidosis (DKA) within 2 weeks after the initial administration of atezolizumab. Another patient had developed type 1 diabetes mellitus (T1DM) during the prior nivolumab treatment and then developed DKA due to an infection after the initiation of atezolizumab. Both of them had high-risk human leukocyte antigen-DR/DQ types relevant to T1DM. These results demonstrate the potential efficacy of PD-L1 inhibitors to some tumors that have acquired resistance to PD-1 inhibitors and suggest that appropriate managements are required for not only a newly onset of T1DM but also blood glucose control after the development of T1DM during a reiteration of the PD-1/PD-L1 blockade.

DOI： 10.1507/endocrj.EJ20-0769

Web of Science

PubMed

CiNii Research

Comparative study of anti-SARS-CoV-2 antibody testing: Relationship between target antigen and immunoglobulin isotype Reviewed International journal

KIM Jeong Hui, KIKUCHI Ryosuke, SUZUKI Atsuo, WATARAI Rika, YOKOYAMA Satoru, MORISE Masahiro, YAGI Tetsuya, MATSUSHITA Tadashi

Japanese Journal of Medical Technology Vol. 69 ( 4 ) page： 554 - 561 2020.10

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Japanese Association of Medical Technologists

As the novel coronavirus disease (COVID-19) pandemic evolves, anti-SARS-CoV-2 antibody (Ab) testing has emerged as an additional or alternative tool for COVID-19 diagnosis. The two antigens used in serological test are the nucleocapsid protein (N) and the spike protein S1 domain (S). In this study, we aimed to validate the performance of seven types of commercial lateral flow immunoassay (LFIA) kits and four types of antibody detection reagents using autoanalyzers as serological testing for COVID-19. Seven types of LFIA kits were purchased from five companies, Kurabo, RayBiotech, Innovita Biological Technology, LumiQuick Diagnostics, and Lepu Medical Technology. Four types of antibody detection reagents were obtained from three companies, Abbot, Roche Diagnostics, and Ortho-Clinical Diagnostics. We tested sequential sera from two patients diagnosed as having COVID-19 by reverse transcription (RT)-quantitative polymerase chain reaction (qPCR). The IgG Ab against the SARS-CoV-2 N protein was detected earlier than IgM Ab, whereas IgM and IgG Ab against the SARS-CoV-2 S protein were detectable from the early stage of infection. These results suggest that S-based Ab detection has a potential for the early detection of SARS-CoV-2 in hospitals, clinics, and test laboratories.

DOI： 10.14932/jamt.20-71

CiNii Research

Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study Reviewed International coauthorship International journal

Seto, T; Hayashi, H; Satouchi, M; Goto, Y; Niho, S; Nogami, N; Hida, T; Takahashi, T; Sakakibara-Konishi, J; Morise, M; Nagasawa, T; Suzuki, M; Ohkura, M; Fukuhara, K; Thurm, H; Peltz, G; Nishio, M

CANCER SCIENCE Vol. 111 ( 10 ) page： 3726 - 3738 2020.10

Clinical burden of immune checkpoint inhibitor-induced pneumonitis Reviewed International journal

Sakamoto, K; Fukihara, J; Morise, M; Hashimoto, N

RESPIRATORY INVESTIGATION Vol. 58 ( 5 ) page： 305 - 319 2020.9

Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer Reviewed International journal

Matsui, A; Morise, M; Tanaka, I; Ozone, S; Matsuzawa, R; Koyama, J; Hase, T; Hashimoto, N; Sato, M; Hasegawa, Y

CANCER INVESTIGATION Vol. 38 ( 7 ) page： 424 - 430 2020.8

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation Reviewed International journal

Tanaka, I; Morise, M; Miyazawa, A; Kodama, Y; Tamiya, Y; Gen, S; Matsui, A; Hase, T; Hashimoto, N; Sato, M; Hasegawa, Y

CLINICAL LUNG CANCER Vol. 21 ( 3 ) page： 273 - + 2020.5

Reply to "Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With NoneSmall-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors" Reviewed International journal

Fukihara, J; Sakamoto, K; Koyama, J; Ito, T; Iwano, S; Morise, M; Ogawa, M; Kondoh, Y; Kimura, T; Hashimoto, N; Hasegawa, Y

CLINICAL LUNG CANCER Vol. 21 ( 3 ) page： E205 - E205 2020.5

UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer Reviewed International journal

Goto, D; Komeda, K; Uwatoko, N; Nakashima, M; Koike, M; Kawai, K; Kodama, Y; Miyazawa, A; Tanaka, I; Hase, T; Morise, M; Hasegawa, Y; Kawabe, T; Sato, M

CANCER INVESTIGATION Vol. 38 ( 4 ) page： 240 - 249 2020.4

　 PREV - NEXT 　

<MORISE Masahiro>

Papers - MORISE Masahiro